Literature DB >> 9021178

Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones.

C M Bebear1, J M Bové, C Bebear, J Renaudin.   

Abstract

Fluoroquinolone-resistant mutants of Mycoplasma hominis were selected in vitro from the PG21 susceptible reference strain either by multistep selection on increasing concentrations of various fluoroquinolones or by one-step selection on agar medium with ofloxacin. The quinolone resistance-determining regions (QRDR) of the structural genes encoding the A and b subunits of DNA gyrase were amplified by PCR, and the nucleotide sequences of eight multistep-selected resistant strains were compared to those of susceptible strain PG21. Four high-level resistant mutants that were selected on norfloxacin or ofloxacin contained a C-to-T transition in the gyrA QRDR, leading to substitution of Ser-83 by Leu in the GyrA protein. Analysis of the sequence of the gyrB QRDR of the eight multistep-selected mutants did not reveal any difference compared to that of the gyrB QRDR of the reference strain M. hominis PG21. Similar analyses of eight one-step-selected mutants did not reveal any base change in the gyrA and gyrB QRDRs. These results suggest that in M. hominis, like in other bacterial species, a gyrA mutation at Ser-83 is associated with fluoroquinolone resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021178      PMCID: PMC163700     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

Review 1.  Mycoplasmal genetics.

Authors:  K Dybvig
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

Review 2.  Bacterial evolution.

Authors:  C R Woese
Journal:  Microbiol Rev       Date:  1987-06

3.  Mycoplasma pneumoniae DNA gyrase genes.

Authors:  S D Colman; P C Hu; K F Bott
Journal:  Mol Microbiol       Date:  1990-07       Impact factor: 3.501

4.  Increase in resistance of Mycoplasma hominis to tetracyclines.

Authors:  M C Cummings; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.

Authors:  J Yamagishi; H Yoshida; M Yamayoshi; S Nakamura
Journal:  Mol Gen Genet       Date:  1986-09

7.  Structure and function of the region of the replication origin of the Bacillus subtilis chromosome. III. Nucleotide sequence of some 10,000 base pairs in the origin region.

Authors:  S Moriya; N Ogasawara; H Yoshikawa
Journal:  Nucleic Acids Res       Date:  1985-04-11       Impact factor: 16.971

8.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  [Comparative activity of minocycline and doxycycline on mycoplasmas pathogenic for man].

Authors:  C Bebear; P Cantet; H Renaudin; C Quentin
Journal:  Pathol Biol (Paris)       Date:  1985-06
View more
  13 in total

1.  Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.

Authors:  C M Bébéar; O Grau; A Charron; H Renaudin; D Gruson; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.

Authors:  C M Bébéar; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

3.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.

Authors:  G E Kenny; P A Young; F D Cartwright; K E Sjöström; W M Huang
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.

Authors:  C M Bebear; H Renaudin; A Charron; D Gruson; M Lefrancois; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.

Authors:  C M Bébéar; H Renaudin; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 8.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

9.  Antimicrobial Resistance in Clinical Ureaplasma spp. and Mycoplasma hominis and Structural Mechanisms Underlying Quinolone Resistance.

Authors:  Ting Yang; Lianlian Pan; Ningning Wu; Lin Wang; Zhen Liu; Yingying Kong; Zhi Ruan; Xinyou Xie; Jun Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

10.  In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species.

Authors:  Yingying Kong; Chao Li; Gangfeng Li; Ting Yang; Mohamed S Draz; Xinyou Xie; Jun Zhang; Zhi Ruan
Journal:  Microbiol Spectr       Date:  2022-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.